Olympus has signed a definitive agreement to acquire BioProtect, a medical device manufacturer aiming to advance cancer care through spacing solutions.
This marks an expansion of Olympus' contributions to oncology and urology in line with its corporate strategy to accelerate technologies and focus on patient safety and outcomes. The $270 million acquisition is expected to be completed by the end of the second quarter of calendar year 2026, subject to customary closing conditions.
BioProtect develops implant technologies that contribute to improving prostate cancer care and enhancing patients' quality of life. Its flagship Balloon Spacer system is designed to provide consistent spacing between the prostate and other critical structures, protecting healthy tissues during prostate cancer radiation therapies.
After treatment, the implant naturally biodegrades. Following its commercial introduction in 2023, the Balloon Spacer has been used in more than 11,000 procedures worldwide, with studies indicating the device's contribution to preserving gastrointestinal, urinary and sexual functions for patients.
The transaction helps Olympus expand its portfolio in adjacent therapeutic areas related to endoscopy, including the gastrointestinal and urological fields, and enhance its value proposition across the entire care pathway.
